Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma

References

• Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Shepherd J D, Sutherland H J, Nevill T J, Nitta J, Le A, et al. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2007; 13: 925–931
   PubMed Web of Science ®Google Scholar
• Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. European group for bone marrow transplantation. N Engl J Med 1991; 325: 1267–1273
   PubMed Web of Science ®Google Scholar
• Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, et al. T-cell – depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001; 98: 934–939
   PubMed Web of Science ®Google Scholar
• Surveillance Epidemiology and End Results. National Cancer institute, Available from: http://seer.cancer.gov/statfacts/html/mulmy.html. Cited 20 November 2008
   Google Scholar
• Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209–216
   PubMed Web of Science ®Google Scholar
• Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukaemia working party of the EBMT. Blood 2005; 105: 4532–4539
   PubMed Web of Science ®Google Scholar
• Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367–373
   PubMed Web of Science ®Google Scholar
• Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110–1120
   PubMed Web of Science ®Google Scholar
• Garban F, Attal M, Michallet M, Hulin C, Bourhis J H, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474–3480
   PubMed Web of Science ®Google Scholar
• Durie B G, Harousseau J L, Miguel J S, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473
   PubMed Web of Science ®Google Scholar
• Hunter H M, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, et al. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning – evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005; 128: 496–502
   PubMed Web of Science ®Google Scholar
• Bjorkstrand B B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European group for blood and marrow transplantation. Blood 1996; 88: 4711–4718
   PubMed Web of Science ®Google Scholar
• Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 2003; 32: 1145–1151
   PubMedGoogle Scholar
• Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
   PubMed Web of Science ®Google Scholar
• Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434–2441
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole D H, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793
   PubMed Web of Science ®Google Scholar
• Gertz M A, Ansell S M, Dingli D, Dispenzieri A, Buadi F K, Elliott M A, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008; 83: 1131–1138
   PubMed Web of Science ®Google Scholar
• Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087
   PubMed Web of Science ®Google Scholar
• Gahrton G, Iacobelli S, Bandini G, Bjorkstrand B, Corradini P, Crawley C, et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica 2007; 92: 1513–1518
   PubMed Web of Science ®Google Scholar